Introduction: Breast cancer is the most frequent solid malignancy in women. Omentin-1 is synthesized by visceral adipose tissue, placenta, and ovary and its production is altered in some cancers. The aim of this study was to assess omentin-1 as a diagnostic marker in patients with breast cancer. Methods: The participants of the study included 90 women (45 patients with breast cancer and 45 healthy women as control group). In addition to anthropometric and blood parameters analysis, omentin-1 serum levels were measured by enzyme-linked immunosorbent assays method. Receiver operator characteristic curve and positive and negative predictive values (PPV and NPV) were calculated to define diagnostic accuracy. Results: Serum omentin-1 level in breast cancer patients (157 ng/L ± 66 ng/L, mean ± SD) was significantly lower than that of the control group (217 ng/L ± 75 ng/L, mean ± SD). There was no significant correlation between omentin-1 levels and anthropometric and blood parameters. The best cut-off point for the diagnosis of breast cancer was at 146 ng/L. The sensitivity and specificity for omentin-1 with 95% CI (0. 611 to 0. 837) were 60% and 85%, respectively. Calculated PPV and NPV at the 146 ng/L cut-off point were 88. 8% and 51. 5%, respectively. Conclusion: Breast cancer patients had significantly lower serum level of omentin-1 than healthy women. Omentin-1 may be beneficial as a screening test along with the early-approved methods in the diagnosis of patients with breast cancer.

Metabolic syndrome (MetS) as a collection of obesity-associated disorders is associated with inflammation, oxidative stress, pro-thrombotic state, elevated risk of developing cardiovascular disease and type 2 diabetes. Adiponectin is one of the most abundant peptide hormones derived from adipose tissue. This protein plays a major role in glucose and lipid metabolism and prevents development of vascular changes. Anti-oxidative and anti-inflammatory effects are the other features of adiponectin. Hypoadiponectinemia is associated with hypertension and pro-thrombotic state. In this review, we discuss the crucial role of adiponectin in prevention of metabolic syndrome considering its effects on the components of this syndrome. Pharmacological interventions and lifestyle modification may increase plasma adiponectin level or tissue sensitivity which seems to be a promising target for prevention and therapeutic approaches of MetS and related diseases.